Normal function · from ai-gene-review (P54289, commit 79fe13b38970) · AI-generated, not KB evidence

Alpha-2/delta-1, the founding member of the four-gene mammalian alpha-2/delta family and an auxiliary subunit of high-voltage-activated calcium channels. The single precursor is cleaved and disulphide-linked into an extracellular alpha-2 chain and a membrane-attached delta chain, and the mature protein is tethered to the outer face of the plasma membrane through a GPI anchor; its extracellular region carries VWA (with a MIDAS motif) and Cache domains. Assembled with a pore-forming CaV1 or CaV2 alpha-1 subunit and a cytoplasmic CaV-beta subunit, it raises calcium-current density and shifts voltage-dependent activation to more negative potentials, largely by increasing the number of channels at the cell surface rather than by conducting ions itself. It is expressed in skeletal and cardiac muscle T-tubules, in vascular smooth muscle, and broadly in neurons, where it concentrates at presynaptic terminals. It is the high-affinity binding site for the gabapentinoid drugs gabapentin and pregabalin. Biallelic loss-of-function variants cause an early-onset developmental and epileptic encephalopathy, and missense variants have been associated with short-QT and Brugada-like cardiac syndromes. Two further roles are proposed and contested. The first is that alpha-2/delta-1 is the neuronal thrombospondin receptor that drives excitatory synaptogenesis; a conditional triple knockout of presynaptic alpha-2/delta-1, -2 and -3 found synapse development, active-zone ultrastructure and transsynaptic alignment intact and reassigned presynaptic alpha-2/delta to setting synaptic gain through Munc13-1, while astrocyte-conditioned-medium experiments continue to support a postsynaptic thrombospondin-1 receptor role. The second is that alpha-2/delta-1 forms a gabapentin-sensitive complex with NMDA receptors, independently of calcium channels, and promotes their synaptic trafficking in chronic pain; this model rests almost entirely on work from a single laboratory and has not been independently replicated.

Alpha-2/delta-1 is a constitutive auxiliary subunit of high-voltage-activated calcium channel complexes. Assembled with a CaV1 or CaV2 pore-forming alpha-1 subunit and a cytoplasmic CaV-beta subunit, it is required for the complex to produce a normal calcium current. It contributes no pore of its own - the mature protein is a disulphide-linked extracellular alpha-2 chain plus a membrane-attached delta chain, GPI-anchored on the outer face of the plasma membrane - so its participation in conduction is recorded as a contribution to a complex-level activity rather than an activity it independently enables. Deployed in skeletal and cardiac muscle T-tubules and at neuronal presynaptic terminals.
Separately from being counted as part of the conducting complex, alpha-2/delta-1 modulates that complex. It raises peak calcium-current density and shifts voltage-dependent activation to more negative potentials, and it does so principally by increasing the number of channels delivered to and retained at the plasma membrane rather than by changing the unitary behaviour of the alpha-1 subunit. This trafficking-and-gating modulation is the subunit's own contribution, it is what disease variants perturb, and it is the property the 2025 presynaptic triple knockout confirmed while overturning the synaptogenic claims. It is also the reason gabapentinoids, which bind alpha-2/delta-1, act on neuronal excitability despite having little direct effect on calcium current.
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
Genetic Developmental and Epileptic Encephalopathy causative
mechanism: Genetic Lesion in an Ion Channel or Synaptic Gene
subtype: DEE110
scoped to subtype: DEE110
Short QT Syndrome untyped
Causative
mechanism: Ion-channel gain- and loss-of-function variants
subtype: SQTS6
scoped to subtype: SQTS6
ClinGen gene–disease validity · snapshot 2026-10-03 · matched to entries by MONDO

An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.

ClinGen diseaseMOIClassificationdismech entry
short QT syndrome MONDO:0000453 AD Disputed
2020-09-05
Mechanism modules · computed from kb/

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.